Latest news
Ocugen Reports Q2 2026 Results, Advances OCU410 Phase 3, Secures RMAT Designation and $130 Million Financing - Quiver QuantitativeQuiver Quantitative · Thu, 06 Aug 2026 11:15:00 GMTLexeo's PKP2 cardiomyopathy gene therapy adds RMAT status - AllSciAllSci · Thu, 06 Aug 2026 09:07:22 GMTLexeo Therapeutics’ LX2020 Receives FDA RMAT Designation for PKP2 Cardiomyopathy - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 06 Aug 2026 06:43:58 GMTLexeo wins FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy - BitgetBitget · Wed, 05 Aug 2026 19:40:53 GMTLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 11:00:00 GMTLexeo's heart gene therapy gets FDA status after interim data - Stock TitanStock Titan · Wed, 05 Aug 2026 11:00:00 GMTFDA Grants RMAT Designation to Sasineprocel for Parkinson Disease - NeurologyLiveNeurologyLive · Tue, 04 Aug 2026 22:35:24 GMTAspen Neuroscience Receives RMAT Designation for Parkinson's Therapy - SynBioBetaSynBioBeta · Tue, 04 Aug 2026 00:00:00 GMT